Search Results:

25th May

Results of a randomised, controlled, open-label trial involving hospitalised adult patients with confirmed SARS-CoV-2 infection were reported in a recent article in NEJM. Patients were randomly assigned to receive either lopinavir–ritonavir twice a day for 14 days in addition to standard care, or standard care alone.

Based on previous research it has been suggested that protease inhibitors might produce…

10 October 2022

In a recent paper, researchers have found that rebounding to COVID-19 is not likely to be caused by an inefficient or impaired immune response, Looking at 8 patients who have taken nirmatrelvir/ritonavir…

17th April

According to Casadevall A and Pirofski using convalescent sera as passive antibody (Ab) therapy may be an option for the prevention and treatment of COVID-19 that could be available as soon as sufficient numbers of people recover and can donate immunoglobulin-containing serum.

3rd April

In an attempt to avoid repeating the mistakes of the 2014–16 West African Ebola epidemic, where clinical trials were set up late, leading to the under-recruiting of patients – in the current pandemic researchers have decided to start trials as soon as possible…

1st April

In an unprecedented effort to obtain scientific data during the SARS-CoV-2 pandemic, the World Health Organization (WHO) has announced the new SOLIDARITY trial that would include thousands of patients from around the world (45 countries and counting)…

July 21st, 2016

Today, July 21 2016, the International AIDS Conference held in Durban, South Africa convened the fourth day of its conference. One session of note was known as “Treatment Evolution: New Drugs, New Reality.” Speakers included Drs Jean-Michel Molina, Dr. Alejandro Arenas-Pinto, Dr. Michael Aboud, Dr. Deanna Kerrigan, Dr. Catherine Orell, and Dr. David Margolis. The talk focused on how AIDS treatment regimens needed to be adapted as new drugs have been released…

Nov 27th, 2015

A recent study published in The Lancet showed the efficacy and safety of two infant drug regimens….